Related Experiment Videos
Platelet aggregation, beta-thromboglobulin and platelet factor 4 in diabetes mellitus and in patients with
Insights
Platelet activation markers, beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4), are elevated in diabetic patients. Discriminant analysis using these markers aids in distinguishing subgroups, particularly those with neuropathy.
Area of Science:
- Biochemistry
- Hematology
- Diabetology
Background:
- Diabetic complications are a significant health concern.
- Platelet activation is implicated in the pathogenesis of diabetic complications.
Purpose of the Study:
- To investigate plasma levels of beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4) in diabetic patients.
- To assess platelet aggregation response in relation to diabetic complications.
- To explore the utility of these markers in classifying diabetic subgroups.
Main Methods:
- Studied 155 subjects: 48 normals, 36 diabetics without complications, 44 with complications, and 27 with macroangiopathy.
- Measured plasma beta-TG and PF4 levels.
- Assessed platelet aggregation response to ADP and platelet activating factor (PAF).
- Utilized discriminant analysis for subgroup classification.
Main Results:
- Elevated beta-TG and PF4 levels were observed in diabetic patient groups compared to normals.
- No significant correlation found between beta-TG levels and the stages of retinopathy, macroangiopathy, or nephropathy.
- Platelet aggregation response was enhanced at lower stimulator concentrations.
- Discriminant analysis effectively distinguished subgroups, especially those with nephropathy and neuropathy.
Conclusions:
- Elevated beta-TG and PF4 suggest increased platelet activation in diabetes.
- These markers, along with aggregation data, can aid in identifying specific diabetic complications like nephropathy and neuropathy.
- Further research is warranted to explore the therapeutic implications of targeting platelet activation in diabetes.
Abstract:
We have studied 155 subjects, 48 normals, 36 diabetics without complications, 44 with complications and 27 patients with macroangiopathy. beta-Thromboglobulin (beta-TG) and platelet factor 4 (PF4) are elevated in the patients groups. There is no correlation between the plasma levels of beta-TG and the stages of either retinopathy or macroangiopathy or nephropathy. The difference is more marked between normals and diabetics with neuropathy (p = 0.026). The aggregation response to ADP and platelet activating factor (PAF) is enhanced at lower stimulator concentration. Using the beta-TG, PF4 and aggregation values the discriminant analysis allows a distinction of several subgroups especially with nephropathy and neuropathy (Table 6).